Proqr Therapeutics N.V. cash flow statement

In fiscal 2025, Proqr Therapeutics N.V.'s operations generated −$59.7m of cash; it spent $1.2m on capital projects, leaving free cash flow of −$60.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Proqr Therapeutics N.V.: cash flow statement, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−31	−72	23	−39	−60
Depreciation and amortisation	3	3	3	3	3
Stock-based pay	7	3	3	3	5
Capital spending	1	1	1	2	1
Free cash flow	−31	−73	22	−41	−61
Free cash flow after stock pay	−39	−76	18	−44	−65

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CTMX vs PRQR CELU vs PRQR PRQR vs SCYX KROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Proqr Therapeutics N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Proqr Therapeutics N.V.